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CYP108D1 fromNovosphingobium aromaticivoransDSM12444
binds a range of aromatic hydrocarbons such as phenanthrene,
biphenyl and phenylcyclohexane. Its structure, which is
reported here at 2.2 A˚ resolution, is closely related to that
of CYP108A1 (P450terp), an -terpineol-oxidizing enzyme.
The compositions and structures of the active sites of these
two enzymes are very similar; the most significant changes are
the replacement of Glu77 and Thr103 in CYP108A1 by Thr79
and Val105 in CYP108D1. Other residue differences lead to a
larger and more hydrophobic access channel in CYP108D1.
These structural features are likely to account for the weaker
-terpineol binding by CYP108D1 and, when combined with
the presence of three hydrophobic phenylalanine residues in
the active site, promote the binding of aromatic hydrocarbons.
The haem-proximal surface of CYP108D1 shows a different
charge distribution and topology to those of CYP101D1,
CYP101A1 and CYP108A1, including a pronounced kink in
the proximal loop of CYP108D1, which may result in poor
complementarity with the [2Fe–2S] ferredoxins Arx, putida-
redoxin and terpredoxin that are the respective redox partners
of these three P450 enzymes. The unexpectedly low reduction
potential of phenylcyclohexane-bound CYP108D1 (401 mV)
may also contribute to the low activity observed with these
ferredoxins. CYP108D1 appears to function as an aromatic
hydrocarbon hydroxylase that requires a different electron-
transfer cofactor protein.
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PDB Reference: CYP108D1,
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1. Introduction
The cytochromes P450 (CYPs) are a superfamily of haem-
containing monooxygenases that are found in virtually all
living organisms (Ortiz de Montellano, 2005; Sigel et al., 2007).
P450 enzymes accept a diverse range of substrates, resulting
in many functional roles, including the biosynthesis of endo-
genous compounds, the degradation of xenobiotics and drug
metabolism. Their primary function is C—H bond oxidation,
although other reactions such as dealkylation, phenol
coupling, alkene epoxidation, heteroatom oxidation and
reductive dehalogenation have also been reported (Guen-
gerich, 2001; Cryle et al., 2003; Isin & Guengerich, 2007). P450
enzymes are drug targets and their potential applications in
the synthesis of drug metabolites and fine chemicals have led
to sustained efforts to discover new activity and to understand
their substrate specificity and protein-recognition interactions
with electron-transport proteins for the reconstitution of high
substrate oxidation activity.
Novosphingobium aromaticivorans DSM12444 is a Gram-
negative strictly aerobic bacterium found in soil, water and
coastal plain sediments (Takeuchi et al., 2001). It is able to
metabolize and degrade polyaromatic hydrocarbons and other
aromatic contaminants (Fredrickson et al., 1991) and has been
reported to be a potential initiator of primary biliary cirrhosis
(Kaplan, 2004). Its genome revealed many genes involved in
the catabolism of aromatic compounds distributed over the
chromosomal DNA and two large plasmids pNL1 (180 kbp)
and pNL2 (480 kbp) (http://genome.jgi-psf.org/finished_microbes/
novar/novar.home.html; Romine et al., 1999). Therefore,
N. aromaticivorans and its enzymes have potential uses in
biocatalysis and bioremediation. We have investigated the
monooxygenase enzymes from this bacterium in order to
assess their potential for applications in C—H bond oxidation.
16 potential cytochrome P450 genes that belong to 12 different
cytochrome P450 families have been identified. The produc-
tion, purification and screening of potential substrates for the
majority of these CYP enzymes have been reported (Bell &
Wong, 2007). The substrate range of the N. aromaticivorans
cytochrome P450 complement is broad and includes mono-
terpenoids, sesquiterpenoids, alkanes, polyaromatic hydro-
carbons and chlorinated benzenes (Bell & Wong, 2007).
A class I electron-transfer system from N. aromaticivorans
consisting of an NADH-dependent ferredoxin reductase
(ArR) and a [2Fe–2S] ferredoxin (Arx) has been shown to
support the monooxygenase activity of CYP111A2 and the
four CYP101 enzymes from this bacterium (Bell, Dale et al.,
2010; Yang et al., 2010). The crystal structures of CYP101C1,
CYP101D1, CYP101D2, ArR and Arx have been reported
(Ma et al., 2011; Yang et al., 2010, 2011). These structures, and
the kinetic behaviour of the enzymes, reveal that electrostatic
interactions are likely to be important in protein–protein
recognition, binding and electron transfer (Yang et al., 2010).
CYP108D1 from N. aromaticivorans (UniProt Q2G3H6) is
a homologue of P450terp (CYP108A1) from a Pseudomonas
species (Fruetel et al., 1994). The crystal structure of CYP108A1,
which hydroxylates -terpineol to yield 7-hydroxyterpineol,
has been reported and its substrate-binding mode has been
modelled (Hasemann et al., 1994). -Terpineol also binds to
CYP108D1, but the haem spin state only shifts to 40% high
spin compared with >95% high spin in CYP108A1. Unusually,
CYP108D1 shows large haem spin-state shifts with aromatic
hydrocarbons such as phenanthrene (90%), fluorene (70%),
p-cymene (60%) and naphthalene (50%) (Bell &Wong, 2007).
The activity of CYP108D1 is low when coupled to Arx and
other [2Fe–2S] ferredoxins such as putidaredoxin (Pdx) from
the CYP101A1 system (Bell & Wong, 2007) and terpredoxin
(Tdx), the electron-transfer partner of CYP108A1 (Peterson
et al., 1992). In order to better understand the preference of
CYP108D1 for more hydrophobic substrates and its low
activity with the [2Fe–2S] ferredoxins tested, we have solved
its crystal structure at 2.2 A˚ resolution and studied its
substrate binding, redox properties and enzyme kinetics in
more detail.
2. Methods
2.1. General
General DNA and microbiological experiments were
carried out by standard methods (Sambrook et al., 1989). The
genomic DNA of N. aromaticivorans (ATCC 700278D-5) was
obtained from ATCC-LGC Promochem, UK. KOD poly-
merase, which was used for the PCR steps, and the pET28a
vector were from Merck Biosciences, UK; other enzymes for
molecular biology were from New England Biolabs, UK.
General reagents and organic substrates and product stan-
dards were from Sigma–Aldrich or Merck, UK. NADH and
yeast alcohol dehydrogenase were from Roche Diagnostics,
UK. Isopropyl -d-1-thiogalactopyranoside (IPTG), growth
media and buffer components were from Melford Labora-
tories, UK, Invitrogen, USA or the Beijing Chemical Com-
pany, People’s Republic of China.
2.2. Cloning, expression and purification
The gene encoding full-length CYP108D1 was cloned into
the vector pET28a(+) using the NdeI and HindIII restriction
sites in order to incorporate an N-terminal 6His tag (Bell &
Wong, 2007). The protein was then produced using Escher-
ichia coli strain BL21 (DE3). The cells were grown in LB
medium containing 30 mg l1 kanamycin at 310 K for 5 h and
recombinant protein production was induced with 0.5 mM
IPTG for 10 h at 301 K. The cells were harvested by centri-
fugation, resuspended in phosphate-buffered saline buffer pH
7.4 (PBS) and lysed by sonication at 277 K. The crude extracts
were centrifuged at 20 000g for 1 h to remove cell debris and
the soluble fraction was loaded onto an Ni2+-chelating affinity
column (2 ml; GE Healthcare, USA) pre-equilibrated with
PBS. The column was washed with PBS containing 20 mM
imidazole and the protein was eluted from the column using
PBS containing 300 mM imidazole. CYP108D1 was buffer-
exchanged into buffer A (20 mM Tris pH 8.0) before being
loaded onto a Resource Q column (1 ml; GE Healthcare). The
protein was eluted using a linear gradient of 0–1M NaCl in
buffer A. A Superdex 200 size-exclusion chromatography
column (10  300 mm; GE Healthcare) was used for further
purification and was eluted with buffer A containing 150 mM
NaCl. The purity of CYP108D1 was estimated to be greater
than 95% by SDS–PAGE analysis (Supplementary Fig. S1a1),
which corresponds to an A418/A280 ratio of 1.9 (Supple-
mentary Fig. S1b1). The concentration of CYP108D1 was
estimated using "446–490 = 91 mM
1 cm1 for the CO differ-
ence spectrum (Omura & Sato, 1964). Using this value, the
extinction coefficient for the ferric resting state of CYP108D1
was estimated to be "417 = 111 mM
1 cm1.
Site-directed mutagenesis of CYP108D1 was performed
using the Stratagene QuikChange mutagenesis kit with the
primer 50-CGACCCGACGCGCGTGGCCAACCGCCATC-
TG-30 and its reverse complement to generate the Pro365Val
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1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: KW5040). Services for accessing this material are described at the
back of the journal.
mutant (the mutated triplet codon is highlighted in bold;
Eurofins MWGOperon, UK). The mutation was confirmed by
DNA sequencing (Geneservice, Oxford University). The gene
encoding full-length terpredoxin (Tdx) was provided in the
vector pET23a(+) by Professor Tom Pochapsky (Mo et al.,
1999). The protein was produced and purified according to
the published protocol for PuxB from Rhodopseudomonas
palustris (except that the antibiotic in the growth medium was
changed to ampicillin; Bell, Xu et al., 2010) and the purity of
Tdx was assessed by UV–Vis spectroscopy (Mo et al., 1999).
Other proteins used in this study were produced and purified
as described previously (Bell, Dale et al., 2010; Bell et al., 2001;
Bell, Xu et al., 2010; Peterson et al., 1990; Xu et al., 2009).
Proteins were stored at 253 K in 50 mM Tris pH 7.4 containing
50%(v/v) glycerol.
2.3. Crystallization and data collection
The purified CYP108D1 protein was concentrated to
40 mg ml1 in crystallization buffer (20 mM Tris pH 8.0).
Crystals of CYP108D1 were obtained using the hanging-drop
vapour-diffusion method at 291 K. 1 ml protein solution
(40 mg ml1) was mixed with 1 ml reservoir solution (0.2M
lithium sulfate, 0.1M Tris pH 8.3, 27% PEG 4000) and
equilibrated against 300 ml of the same solution. Diffraction-
quality crystals were obtained after approximately one week.
X-ray diffraction data were collected on a Rigaku R-AXIS
IV++ image plate using Cu K radiation ( = 1.5418 A˚) from
an in-house Rigaku MicroMax-007 rotating-anode X-ray
generator operating at 40 kV and 20 mA. The crystals were
cryoprotected by addition of 20%(v/v) glycerol to the reser-
voir solution. The diffraction data set was indexed, integrated
and scaled with theHKL-2000 package (Otwinowski &Minor,
1997). The crystals belonged to space group R32, with unit-cell
parameters a = 93.9, b = 93.9, c = 299.3 A˚. Complete data-
collection statistics are summarized in Table 1.
2.4. Structure determination and refinement
For the structure determination of CYP108D1, the phases
were solved by the molecular-replacement (MR) method
using the program Phaser in the CCP4 suite (McCoy et al.,
2007; Winn et al., 2011). The structure of CYP108A1 (PDB
entry 1cpt; Hasemann et al., 1994) was used as a search model.
The initial model was rebuilt with Coot (Emsley & Cowtan,
2004) and refined with ARP/wARP (Perrakis et al., 1999) and
REFMAC5 (Murshudov et al., 2011). The stereochemical
quality of the refined structure was checked with the program
MolProbity (Chen et al., 2010). A summary of the structure-
refinement statistics is provided in Table 1. The coordinates of
the crystal structure of CYP108D1 have been deposited in the
PDB (http://www.pdb.org; Berman et al., 2000) with accession
code 3tkt.
2.5. Substrate-docking experiments
Phenylcyclohexane and phenanthrene were docked into the
structure of CYP108D1 usingAutoDock 4 (Morris et al., 1998).
Preparation of the macromolecule and ligands was performed
using the AutoDock Tools program. The grid box was centred
on the active site of CYP108D1 and the docking search was
carried out using the genetic algorithm method. AutoGrid and
AutoDock were run using the default parameters of the
program. A total of 50 simulations were run and the lowest-
energy docking solutions were chosen for further analysis.
2.6. Substrate binding
Glycerol was removed immediately before use by gel
filtration on a 5 ml PD-10 column (GE Healthcare) eluted
with 50 mM Tris pH 7.4. UV–Vis spectra and spectroscopic
activity assays were recorded at 303  0.5 K on a Varian
CARY-50 or CARY-1E spectrophotometer. For substrate-
binding assays the CYP108D1 enzyme was diluted to0.5 mM
in 50 mM Tris pH 7.4 (2.5 ml). Aliquots of substrate (0.5–2 ml)
were added using a Hamilton syringe from a 1, 10 or 100 mM
stock solution in DMSO. The sample was mixed and the
spectrum was acquired between 700 and 250 nm and the peak-
to-trough difference in absorbance was recorded. Further
aliquots of substrate were added until the peak-to-trough
difference did not shift further. The dissociation constants Kd
were obtained by fitting the peak-to-trough difference, scaled
for dilution, against substrate concentration to a hyperbolic
function,
A ¼ Amax  ½S
Kd þ ½S
; ð1Þ
where A is the peak-to-trough absorbance difference,
Amax is the maximum absorbance difference and [S] is the
substrate concentration.
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Table 1
Data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Data-collection statistics
Space group R32
Unit-cell parameters (A˚) a = b = 93.9, c = 299.3
Wavelength (A˚) 1.5418
Resolution (A˚) 50–2.2 (2.28–2.20)
hI/(I)i 24.3 (4.5)
Completeness (%) 100 (100)
Average multiplicity 7.3 (7.2)
Rmerge† (%) 8.3 (40.1)
Structure-refinement statistics
Resolution (A˚) 50–2.2
Average B factor (A˚2) 27.7
Rwork/Rfree‡ (%) 18.7/23.4
R.m.s. deviation from ideal bond lengths§ (A˚) 0.017
R.m.s. deviation from ideal bond angles§ () 1.758
Ramachandran favoured (%) 96.31
Ramachandran outliers (%) 0.00
MolProbity score 2.41
Poor rotamers (%) 7.60
Clash scores 9.35
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the ith intensity
measurement of reflection hkl and hI(hkl)i is the average intensity from multiple
observations. ‡ Rwork/Rfree =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj, where Fobs and Fcalc are
the observed and calculated structure factors, respectively. § Ideal values are derived
from Engh & Huber (1991).
Several substrates exhibited tight binding, with Kd < 5[E],
and in these instances the data were fitted to the tight-binding
quadratic equation (Williams & Morrison, 1979),
A
Amax
¼ ð½E þ ½S þ KdÞ  fð½E þ ½S þ KdÞ
2  4½E½Sg1=2
2½E ;
ð2Þ
where A is the peak-to-trough absorbance difference,
Amax is the maximum absorbance difference, [S] is the
substrate concentration and [E] is the enzyme concentration.
The high-spin haem content was estimated (to approxi-
mately 5%) by comparison with a set of spectra generated
from the sum of the appropriate percentages of the spectra of
the substrate-free form (>95% low spin, Soret maximum at
418 nm) and the camphor-bound form (>95% high spin, Soret
maximum at 392 nm) of wild-type CYP101A1.
2.7. Product formation
NADH turnover-rate assays were performed with mixtures
(1.2 ml) consisting of 50 mM Tris pH 7.4, 0.5 mM CYP108D1,
5 mM ferredoxin, 0.5 mM ferredoxin reductase and
100 mg ml1 bovine liver catalase. The mixtures were equili-
brated at 303 K for 2 min. Substrates were added as a 100 mM
stock solution in ethanol or DMSO to a final concentration of
0.2–1 mM depending on the substrate solubility. NADH was
added to 320 mM (final A340 = 2.00) and the absorbance at
340 nm was monitored. The rate of NADH consumption was
calculated using "340 = 6.22 mM
1 cm1.
Substrate turnovers for product identification were carried
out using the ArR–Arx electron-transfer system in vitro. The
reactions were performed in 50 mM Tris pH 7.4 (final volume
of 10 ml) using 100 nM of the appropriate CYP enzyme,
500 nM Arx, 100 nM ArR, 100 mg ml1 bovine liver catalase,
100 mM NADH and 90 units of yeast alcohol dehydrogenase
(0.3 mg) as the cofactor-regenerating system. Substrate from a
1:1 ethanol:DMSO stock (final concentration 0.1–1 mM) was
added. After stirring for 4 h at ambient temperature, the
reaction was terminated by freezing. Products were extracted
using ethyl acetate (EtOAc) and identified by co-elution of
the extracts with authentic standards. 4-Phenylcyclohexanol
isomers were produced by reducing 4-phenylcyclohexanone
with excess NaBH4 in EtOH. The reaction was quenched with
H2O before removing volatiles by evaporation. The organics
were extracted using EtOAc. The different 4-phenylcyclo-
hexanol isomers were identified by co-elution of the samples
with a turnover of the CYP101A1 Y96F/V247L mutant with
phenylcyclohexane (conditions as above) using PdR and Pdx
as the electron-transfer proteins, which produced a tenfold
excess of trans-4-phenylcyclohexanol over the cis isomer
(Jones et al., 1996; Bell et al., 1997). 7-Hydroxyterpineol was
produced by adding -pinene oxide (2 mg) to a slight excess
of Hg(NO3)2 in a 1:1 mixture of 50 mM Tris pH 7.4 and THF
(4 ml) (Bluthe et al., 1980; Fruetel et al., 1994). The mixture
was extracted using EtOAc.
Gas-chromatography (GC) analyses were performed on a
ThermoFinnegan Trace GC instrument equipped with an
auto-sampler and a CP-Sil 8 fused-silica column (15 m 
0.25 mm; Varian) or a ThermoFinnegan GC8000top equipped
with a DVF-wax fused-silica column (15 m 0.25 mm; Varian)
both using helium as the carrier gas and flame ionization
detection. The injector and flame ionization detector were
held at 473 and 523 K, respectively (523 and 553 K for larger
polyaromatic hydrocarbons). The oven parameters are given
in Table 2. The retention times for the substrates and products
on the DVF-wax column were (retention times on the CP-Sil 8
column are given in parentheses): 18.8 (8.35) min for fluorene,
25.1 (9.2) min for 9-fluorenone, 29.1 (9.3) min for 9-hydroxy-
fluorene, 12.9 (6.85) min for biphenyl, 23.8 (7.9) min for
2-hydroxybiphenyl, 31.9 (9.0) min for 3-hydroxybiphenyl,
32.3 (9.1) min for 4-hydroxybiphenyl, 7.9 (4.9) min for
-terpineol, 22.6 (7.5) min for 7-hydroxyterpineol, (4.3) min
for -pinene oxide, 4.1 (3.0) min for p-cymene, 15.5 (6.05) min
for 4-isopropylbenzylalcohol, 17.2 (6.0) min for thymol,
17.6 (6.15) min for carvacrol, 10.9 (4.9) min for p-,-tri-
methylbenzylalcohol, 7.4 (6.2) min for phenylcyclohexane,
19.2 (8.1) min for 4-phenylcyclohexanone, 21.2 (8.2) min for
trans-4-phenylcyclohexanol, 20.6 (8.2) min for cis-4-phenyl-
cyclohexanol, 8.6 (4.8) min for naphthalene, 28.2 (7.8) min for
1-naphthol, 29.1 (7.9) min for 2-naphthol, 24.7 (9.45) min for
phenanthrene, 31.3 min for 2-phenanthrol, 30.4 min for 9,10-
phenanthrenequinone and 29.4 min for 9-phenanthrol.
2.8. Redox titrations
Redox titrations were carried out in a custom-built optically
transparent thin-layer electrode (OTTLE) cell constructed
from a quartz cuvette of 0.1 cm path length as described
previously (Whitehouse et al., 2010, 2011). Anaerobic condi-
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Table 2
GC oven parameters.
Substrate CP-Sil DVF-wax
p-Cymene 333 K for 1 min, raise to 423 K at 15 K min1, hold for 3 min and then
raise to 493 K over 1 min and hold for a further 2 min
373 K for 2 min, raise to 473 K at 5 K min1 and hold for
13 min
-Terpineol As p-cymene As p-cymene
Phenylcyclohexane As p-cymene As p-cymene
Naphthalene As p-cymene 373 K for 2 min, raise to 523 K at 5 K min1 and hold for
3 min
Fluorene As p-cymene 373 K for 2 min, raise to 523 K at 5 K min1 and hold for
13 min
Biphenyl As p-cymene As fluorene
Phenanthrene 373 K for 1 min, raise to 523 K at 10 K min1 and hold for 13 min As fluorene
tions were maintained by purging the system continually with
argon that had been sparged through an 10 cm column of
water at room temperature. The cell was held at 298  0.1 K.
The sample volume was approximately 1300 ml, comprising
50–100 mM protein, 5 mM each of methylene blue, anthra-
quinone-1,5-disulfonate, anthraquinone-2,6-disulfonate, anthra-
quinone-2-sulfonate and methyl viologen, 10 mM glucose,
0.2 mg ml1 glucose oxidase, 0.2 mg ml1 catalase, 200 mM
NaCl in 50 mM Tris pH 7.4 and, for titrations with the
substrate-bound forms, 1 mM camphor, 500 mM phenylcyclo-
hexane and 2%(v/v) DMSO. Glucose, glucose oxidase and
catalase were included to convert residual dioxygen to water.
Sample preparation and cell assembly took place in a Belle
Technology glove box (O2 < 5 p.p.m.). Spectra were acquired
for at least 40 min to allow equilibration. Longer periods
produced no further changes to the spectrum within the
sensitivity of the spectrometer. Data were corrected for
baseline drifts by a zeroth-order adjustment based on the
average optical density from 775 to 800 nm. Because the
absorbance of the peaks in the Soret band was convoluted
by contributions from the reduced form of methyl viologen
(max = 395 nm), the absorbances at 450, 465 and 550 nm were
used for data analysis of the P450 enzymes and those at 415
and 460 nm for the Arx ferredoxin. Data were fitted to a
sigmoid derived from the Nernst equation
AðEÞ ¼ AðEmaxÞ  AðEminÞ
1þ exp½ðEm  EapplÞ=ðRT=nFÞ
þ AðEminÞ; ð3Þ
where A(E) is the absorbance for a given potential, A(Emax)
and A(Emin) are the optical densities for the fully oxidized and
fully reduced chromophore, Em and Eappl are the midpoint
and applied potentials, R is the gas constant, T is the cell
temperature, n is the number of electrons transferred for
the redox couple and F is Faraday’s constant. The values of
A(Emax), A(Emin) and Em were determined by minimizing the
square of the difference between the measured value and the
predicted value, assuming equal weighting of the data. The
value of n was fixed at 1. When n was allowed to vary, values
ranged from 0.86 to 1.24. All potentials relate to the standard
hydrogen electrode.
2.9. Stopped-flow spectrophotometry
The rate constants for the formation of the FeII(CO)
complex, kf, for CYP101D1 and CYP108D1 in the presence of
camphor and phenylcyclohexane were measured at 303 
0.1 K by monitoring the absorbance at 450 nm using an
Applied Photophysics SX20 stopped-flow spectrophotometer
operating in single-wavelength mode in a glove box. Compo-
nents were prepared in 50 mM Tris pH 7.4 saturated with CO
by gently bubbling for 5 min and then purging the headspace
for a further 5 min. SyringeA contained 0.2 mMArR, 2–40 mM
pre-reduced Arx (by the addition of NADH) and syringe B
the appropriate CYP enzyme (2 mM) and the substrate (1 mM
camphor or 500 mM phenylcyclohexane) in 2%(v/v) ethanol.
The components were mixed in a 1:1 ratio.
Data for CYP101D1 with camphor were fitted using the
Pro-Data Viewer software (Applied Photophysics). At a final
concentration of 2.5 mM Arx and 1 mM CYP101D1, the early
part of the data could be fitted to a single exponential with a
rate constant of 22.9  0.8 s1. Although the relative ampli-
tude of this phase varied between experiments, the rate
constant derived from multiphasic fits always fell within a
narrow range for each enzyme.
2.10. EPR
CW EPR experiments were performed using an X-band
Bruker BioSpin GmbH EMX spectrometer equipped with a
high-sensitivity Bruker probehead and an Oxford Instruments
CF935 helium-flow cryostat. Experiments were conducted at
20 K with 0.2–2 mW microwave power, 0.5 mT modulation
amplitude, a microwave frequency of 9.3909 GHz and a
modulation frequency of 100 kHz.
3. Results and discussion
3.1. Overall structure of CYP108D1
The crystal structure of CYP108D1 was solved at 2.2 A˚
resolution using the molecular-replacement method, with the
crystallographic Rwork and Rfree converging to 18.7% and
23.4%, respectively (Table 1). The final model is composed of
one CYP108D1 molecule and 267 water molecules and adopts
the characteristic P450 fold with a mixed / structure (Fig. 1a;
Poulos et al., 1987). CYP108D1 was traced from residues 4 to
430, with the exception of residues 192–209 of the F–G loop,
and consists of 18 -helices, four 310-helices and nine -sheets.
It shares both high sequence similarity (41% identity and 60%
similarity) and structure similarity (r.m.s.d. = 1.2 A˚ for all C
atoms) to CYP108A1 (Supplementary Figs. S2–S4; Hasemann
et al., 1994). The F–G loop was also not resolved in the
CYP108A1 structure, but a high degree of flexibility in this
region is common among P450 structures (Hasemann et al.,
1995; Pochapsky et al., 2010). CYP108D1 contains fewer
-sheets than CYP108A1, and those that are present are
shorter (Supplementary Fig. S2).
3.2. The access channel and the active site
An access channel is observed in the CYP108D1 crystal
structure (Fig. 1b), the entrance of which is comprised of
residues from the B0 and F helices as well as the B–B0 and B0–C
loops. The entrance cannot be defined precisely because the
unresolved F–G loop may act as a flexible ‘lid’ and cover the
observed access channel (Hasemann et al., 1994; Dunn et al.,
2001; Yang et al., 2011). The B0 helix and the B–C and F–G
loops are proposed to be important in substrate recognition
and entry and therefore substrate specificity (Cojocaru et al.,
2007; Li & Poulos, 2004; Bell et al., 2008). The positions of the
B0, F and G helices and the C-terminus of the I helix are
broadly similar to those in CYP108A1. There is a small change
in the position of the F helix in CYP108D1 compared with
CYP108A1, with the N-terminus in CYP108D1 being closer to
the haem and the active site (Fig. 1c). The access channel is
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hydrophobic and is flanked by the residues Val80, Thr82,
Gly86, Ala90, Leu100 and Phe190 (Fig. 1d). These residues
differ significantly from those in the equivalent locations in
CYP108A1, with Val80, Thr82, Gly86, Ala90 and Leu100 in
CYP108D1 replacing Ile78, Tyr80, Asn84, Met88 and Val98 in
CYP108A1, resulting in a wider, more hydrophobic channel in
CYP108D1 (Supplementary Table S1 and Fig. 1e).
At the bottom of this channel is the active site, which is
defined by the residues Thr79, Val101, Ser103, Val105, Gln106,
Phe190, Ile265, Ser268, Ala269, Asp272, Thr273, Val316,
Phe319, Phe416 and Val417 (Figs. 2a, 2b and S5). The active
sites of CYP108A1 and CYP108D1 are broadly similar
(Supplementary Fig. S5 and Table S2). However, Thr79 and
Val105 in CYP108D1 align with Glu77 and Thr103 in
CYP108A1, resulting in a more hydrophobic active site
(Figs. 2a and S5). Additionally, Val101, Gln106, Ile265 and
Ser268 align with Ile99, Ser104, Ala263 and Thr266, and the
side chains of Phe190 and Gln106 of CYP108D1 protrude
further into the active-site pocket than their counterparts in
CYP108A1 (Phe188 and Ser104). The -terpineol hydroxyl
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Figure 1
(a) The overall structure of CYP108D1. The B0, F andG helices are coloured orange, salmon and blue, respectively. The haem is shown in yellow and the
long I helix (magenta) is also labelled. (b) The entrance to the access channel on the distal surface of CYP108D1. The B0, F and G helices define the
entrance to the access channel, which is highlighted by the black circle. (c) Superposition of the B0, F, G and I helices and the haems of CYP108D1 and
CYP108A1 (grey). In general, these regions overlay well, with the exception of the N-terminus of the F helix, which has a different orientation in
CYP108D1. (d) The 2mFo DFc density of the access-channel residues contoured at0.35 e A3. (e) Comparison of the access channels of CYP108D1
(green) and CYP108A1 (pink). The haem and the active-site residues of CYP108D1 are shown in yellow and grey, respectively. The active-site residues
are shown inside the oval. The access channel of CYP108D1 is lined by smaller and more hydrophobic residues. Residue differences in CYP108A1 are
shown in parentheses (Supplementary Table S1).
group has been modelled as binding to Glu77 and Thr103 of
CYP108A1 (Hasemann et al., 1994) and the replacement of
these residues by Thr79 and Val105 would contribute to the
weaker binding of this substrate by CYP108D1. -Terpineol
shifts the CYP108D1 haem spin state to 40% high spin, with
Kd being 156  13 mM, compared with >95% shift and an
association constant of 2.2 106 M with CYP108A1 (Peterson
et al., 1992). Aromatic compounds such as phenanthrene
(90%), fluorene (70%), p-cymene (60%) and naphthalene
(50%) induce larger shifts and show tighter binding with
CYP108D1 than -terpineol (Table 3; Bell & Wong, 2007).
The more hydrophobic and spacious nature of the access
channel and active site is consistent with the ability of
CYP108D1 to bind these molecules.
The thiolato side chain of Cys379 (Fe—S = 2.3 A˚) is the
proximal ligand to the haem iron, which is 0.2 A˚ out of the
porphyrin plane towards Cys379 in CYP108D1 compared with
0.05 A˚ in CYP108A1. The active site and access channel of the
substrate-free forms of most CYP enzymes are occupied by
water molecules (Poulos et al., 1986; Denisov et al., 2005;
Pylypenko & Schlichting, 2004). Only two ordered water
molecules could be modelled in the active site of CYP108D1
(Figs. 2c and 3d). Wat266 is loosely associated with the haem
iron (3.3 A˚) and is offset from an axial position with an
S—Fe—O angle of 161 (2.1 A˚ and 175 in CYP108A1). The
haem of substrate-free CYP108D1 appears to be fully low
spin, with a Soret maximum at 419 nm (Supplementary
Fig. S6). Wat266 is hydrogen bonded to Wat267 (2.4 A˚) and
the carbonyl of Ala269 (3.5 A˚) and presumably contributes to
the low-spin-state haem iron in the substrate-free form. From
the crystal structure it is unclear whether there are other
unresolved water molecules in the active site which could
interact with Wat266. The crystal may hold CYP108D1 in an
open conformation which may be differently solvated to a
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Figure 2
(a) The active site of CYP108D1. The residues located in the active site are shown in green. The identity and positioning of these residues are very similar
to those of CYP108A1 (Supplementary Table S2 and Fig. S5). (b) The 2mFo  DFc density of the active-site residues contoured at 0.35 e A˚3. (c)
Overlay of the haem and the active-site waters of CYP108D1 (yellow, with water molecules in red and the haem iron in orange) and CYP108A1 (grey,
with water molecules in blue and the haem iron in cyan). Wat266 in CYP108D1 is offset from the Fe—S bond, and the Fe—O bond is longer and weaker
compared with that to Wat440 in CYP108A1. (d) The 2mFo DFc density of the haem, Cys379 residue and the active-site water molecules contoured at
0.35 e A˚3.
closed conformation found in solution. Other possible expla-
nations could be that the crystal may have trapped an unusual
ferric high-spin state (in the absence of substrate) or that the
haem iron may have been photoreduced to the ferrous form in
the X-ray beam.
Asp272 and Thr273 are the I-helix acid–alcohol pair of
residues which are important in oxygen activation by P450
enzymes (Denisov et al., 2005; Nagano & Poulos, 2005; Vida-
kovic et al., 1998). The backbone carbonyl of Asp272 forms
a hydrogen bond to the main-chain NH of Ala276. This
orientation is similar to that found in ferric substrate-free
CYP108A1 (Asp270 and Ser274), CYP101D1 (Asp258 and
Asn262), CYP101D2 (Asp257 and Asn261) and CYP101C1
(Asp237 and Ala241) and the ferrous-oxy form of CYP101A1
(Asp251 and Asn255) (Hasemann et al., 1994; Yang et al., 2010,
2011; Ma et al., 2011; Schlichting et al., 2000). There is a
potential short path for proton delivery in CYP108D1 that
leads from the I-helix groove to the protein surface (Zhao et
al., 2005). One water molecule (Wat37) is observed above the
I-helix groove and hydrogen bonds to the carbonyl of Ser268
and the backbone N atom of Asp272. One O atom of Asp272
is hydrogen bonded to Wat163, which is attached to a chain
of water molecules that extends into the bulk solvent
(Wat163–Wat206–Wat240–Wat165–Wat49–Wat17; Supplementary
Fig. S7).
3.3. The substrate range of CYP108D1
A variety of hydrophobic and aromatic substrates were
tested for type I spectral shifts upon binding to CYP108D1.
Substrates containing up to three aromatic rings were found to
bind to CYP108D1, e.g. phenanthrene, fluorene, biphenyl,
p-cymene and phenylcyclohexane. Binding titrations showed
that the tightest binding substrates generally induced a greater
shift of the haem spin state to high spin (Table 3). For example,
phenylcyclohexane binding exhibited the largest shift (95%
high-spin haem) and the tightest binding (Kd = 1.01 
0.06 mM), while biphenyl, naphthalene and -terpineol
induced smaller shifts in the haem-iron spin state and were
correspondingly less tightly bound (Table 3, Figs. 3, S8 and S9).
Phenanthrene showed tighter binding and induced a larger
spin-state shift than fluorene and naphthalene, while other
substrates such as pyrene (	5%) and diphenylmethane (20%)
induced lower spin-state shifts (Supplementary Fig. S8).
The ability of CYP108D1 to bind these highly insoluble
hydrophobic organic molecules would allow it to be used as an
aromatic hydrocarbon monooxygenase in biocatalysis or bio-
remediation (Bell et al., 2003, 2007; Bernhardt, 2006). Given
the similar overall structure and active-site architecture of
CYP108D1 and CYP108A1, the different substrate-binding
profiles of the two enzymes is intriguing. The CYP108 family
is abundant among bacteria, e.g. members can be found in
Erythrobacter, Sphingobium, Caulobacter, Cupriavidus,
Burkholderia, Frankia and Mycobacterium species (Supple-
mentary Fig. S10). The CYP108D and CYP108A subfamilies
are small compared with the CYP108B subfamily, to which the
majority of the members belong (Supplementary Fig. S10;
Fischer et al., 2007). Further investigation will be required to
ascertain the substrate-binding profiles of the other CYP108
enzymes.
The haem spin-state equilibrium in CYP108D1 was further
investigated using EPR spectroscopy. Substrate-free
CYP108D1 was predominantly low spin (Supplementary
Fig. S11). A small contribution from a high-spin species could
be observed in CYP108D1 when compared with substrate-free
CYP101A1, which is fully low spin under similar conditions
(Supplementary Fig. S11). The EPR spectrum of phenyl-
cyclohexane-bound CYP108D1 indicated that there was a
shift of the haem spin state from low to high spin, although a
significant low-spin population was retained at 20 K despite
the large spin-state shift detected by UV–Vis spectroscopy at
303 K (Supplementary Fig. S8). The CYP101A1 control
sample also did not shift completely to a high-spin population
on camphor binding at 20 K, which is in agreement with
published data (Lipscomb, 1980).
Substrate soaking and cocrystallization experiments of
CYP108D1 with identified substrates, including phenylcyclo-
hexane, naphthalene and -terpineol, were unsuccessful and
we were unable to obtain diffracting crystals. Substrate-
docking simulations were therefore performed to provide
insight into potential binding orientations of phenylcyclo-
hexane and phenanthrene. Of the calculated docking results,
the lowest energy orientations were used to analyze the
binding modes. Two of these were found for phenylcyclo-
hexane (Supplementary Fig. S12a and Table S3) and in both
modes the phenyl ring interacts with the side chains of Phe190
and Phe416. In both binding orientations the aliphatic
cyclohexyl ring is nearest to the haem, with the C4 carbon
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Table 3
Substrate-binding data for CYP108D1.
Substrate High-spin haem (%) Kd (mM)
Phenylcyclohexane 95 1.01  0.06
Phenanthrene 90 2.06  0.10
Biphenyl 85 7.30  0.21
Fluorene 70 5.85  0.18
p-Cymene 60 33.8  4.2
Naphthalene 50 46.9  2.8
-Terpineol 40 156  13
Figure 3
Substrate-binding titrations for CYP108D1 with phenanthrene (white
triangles), biphenyl (grey circles) and phenylcyclohexane (black squares).
Aliquots of a 1, 10 or 100 mM stock solution of substrate (0.5–2 ml) were
added to 0.6 mM CYP108D1 in 50 mM Tris pH 7.4. The tight-binding
equation was used for phenylcyclohexane and phenanthrene.
being the closest to the haem iron,
which is consistent with the observed
products of phenylcyclohexane oxida-
tion by CYP108D1 (see below).
Phenanthrene is modelled in the active
site in a similar orientation to one of the
binding modes of phenylcyclohexane,
with the plane of the molecule almost
perpendicular to the haem. The
phenanthrene interacts with Phe190,
Phe319 and Phe416 (Supplementary
Fig. S12b and Table S4). With the caveat
that significant conformational changes
of CYP108D1 are likely to occur on
substrate binding (Yang et al., 2011; Lee
et al., 2010; Savino et al., 2009; Wild-
erman et al., 2010), resulting in a more
closed structure and changes in the
orientation of the amino-acid side
chains, the aromatic residues of
CYP108D1 (Phe190, Phe319 and
Phe416) appear to be important in
substrate binding. For both phenyl-
cyclohexane and phenanthrene the
Phe190 side chain appears to function as
a cap at the top of the active site
(Supplementary Fig. S12).
3.4. The proximal face of CYP108D1
and implications for enzyme activity
The binding site for the electron-
transfer partner is located on the prox-
imal surface of P450 enzymes and a
model of the CYP101A1–Pdx complex
has been reported (Pochapsky et al.,
1996; Kuznetsov et al., 2006). In
N. aromaticivorans an ArR–Arx class I
electron-transfer system supports high monooxygenase
activity (kcat of up to 91 s
1) of CYP101B1, CYP101C1,
CYP101D1, CYP101D2 and CYP111A2, but its activity with
CYP108D1 was lower by three orders of magnitude (Bell,
Dale et al., 2010; Bell & Wong, 2007; Yang et al., 2010). NADH
consumption rates with substrates such as phenylcyclohexane
and phenanthrene, which induce >90% high-spin haem
content, were indistinguishable from the background rate in
the absence of substrate [15–20 nmol min1 (nmol P450)1].
The amount of product detected by gas chromatography (GC)
from these assays was also very low. It seems unlikely that Arx
is the physiological redox partner of CYP108D1. Other elec-
tron-transfer systems, including putidaredoxin reductase
(PdR) and putidaredoxin (Pdx) from P. putida and palus-
trisredoxin reductases (PuR and HaPuR) and palustris-
redoxins (Pux, PuxB and HaPux) from R. palustris CGA009
and HaA2, also gave low activities (Bell, Xu et al., 2010; Bell,
Tan et al., 2010; Peterson et al., 1990). Terpredoxin (Tdx), the
physiological electron-transfer partner of CYP108A1, was
tested using ArR as the ferredoxin reductase, but the activities
were also nugatory. Electron transfer from ArR to Tdx was
confirmed to be efficient by a cytochrome c reduction assay
(Aoki et al., 1998; Lambeth et al., 1979; Bell, Xu et al., 2010).
The reduction of Tdx by ArR was found to have a kcat of 300
17 s1 and KM of 5.9  1.2 mM, compared with 280  12 s1
and 2.9 0.4 mM for Arx reduction by ArR (Yang et al., 2010),
clearly establishing that Tdx is unable to transfer electrons
efficiently to CYP108D1.
Despite the low activities, it was possible to generate suffi-
cient product for detection via gas chromatography (GC)
using an in vitro cofactor-regeneration system (Fig. 4).
Unfortunately, the amount of material was not sufficient for
detailed chemical characterization, but the products could
be identified via GC co-elution experiments using authentic
standards. Phenylcyclohexane was oxidized to trans-
4-phenylcyclohexanol (97%), with cis-4-phenylcyclohexanol
(2%) and 4-phenylcyclohexanone (1%) being formed as
minor products (Supplementary Fig. S13). The selectivity of
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Figure 4
Substrates that bind to CYP108D1. Where identified, the oxidation products from CYP108D1
turnover are included.
phenylcyclohexane oxidation is in agreement with the orien-
tation predicted from computer-modelling calculations
(Supplementary Fig. S12a). p-Cymene was predominantly
oxidized to 4-isopropylbenzyl alcohol (94%), with p-,-
trimethylbenzylalcohol making up the remainder. Naphtha-
lene oxidation resulted in very low levels of 1-naphthol
formation (data not shown) and several other unidentified
products, while -terpineol yielded 7-hydroxyterpineol (the
same product as obtained with CYP108A1; Supplementary
Fig. S13). The remaining substrates, biphenyl, fluorene and
phenanthrene, all produced very low levels of products which
could not be identified from the standards available
(2-phenanthrol, 9-phenanthrol, 9,10-phenanthenequinone,
9-hydroxyfluorene, 9-fluorenone, 2-hydroxybiphenyl, 3-hydroxy-
biphenyl and 4-hydroxybiphenyl; data not shown).
Given the low activities observed with all of the [2Fe–2S]
electron-transfer ferredoxins tested, we compared the prox-
imal faces of the CYP108 and CYP101 families of enzymes
(Figs. 5a and S14a). Directly beneath the haem, the electro-
static potential of the proximal face of CYP108D1 is less
positively charged than those of CYP101C1, CYP101D1 and
CYP101D2. However, it is more positively charged than these
enzymes (and CYP101A1) around the periphery. Electrostatic
interactions have been proposed to play an important role
in binding between Arx and CYP101C1, CYP101D1 and
CYP101D2, with the positively charged proximal faces of the
CYP enzymes interacting with negatively charged residues on
Arx (Yang et al., 2010; Ma et al., 2011; Yang et al., 2011).
Gln378 of CYP108D1, which is the residue preceding the
haem-iron-bound Cys379, replaces arginine residues in
CYP101C1, CYP101D1 and CYP101D2 but aligns with
Leu356 in CYP101A1 and Met376 in CYP108A1 (Supple-
mentary Table S5). Asp121 of CYP108D1 creates a negatively
charged region on the haem-proximal face and aligns with
positively charged Lys residues in the N. aromaticivorans
CYP101 enzymes (Gln117 in CYP101A1 and Asn119 in
CYP108A1; Supplementary Table S5). These residue differ-
ences may have an impact on Arx–CYP108D1 binding and
electron transfer.
The region before the proximal loop, Pro365–Arg368 in
CYP108D1, protrudes from the proximal surface, with the
largest deviation at Ala366 and Gln367 such that Gln367 is
located over the haem, unlike in CYP108A1 (Figs. 5b–e and
S14b). Pro362 in CYP108A1 aligns with Pro365 in CYP108D1,
but the sequences either side of these prolines are different:
Pro365 follows directly from Arg364 in CYP108D1 with the
sequence Arg364-Pro365-Ala366-Asn367, while in CYP108A1
it is Arg362-Phe363-Pro364-Asn365 (Supplementary Fig. S3).
The structural distortion, which is not a consequence of
crystal-packing interactions, may be a result of the different
orientation of Pro365 and in particular the interactions of the
subsequent residues with those of the K and L helices. The
main-chain N atom and side-chain O atom of Asn367 form
hydrogen bonds to the side chains of Glu307 and Arg386
(Fig. 5e). In contrast, the side chain NH2 of Asn365 in
CYP108A1 forms a hydrogen bond to the Glu308 side chain
(in theK helix), even though Arg386 in CYP108D1 aligns with
Lys384 in CYP108A1. There are also hydrogen bonds within
the loop, such as those between the side chain of Arg368 and
the carbonyl O atoms of Ala366 and Asn367, and water-
bridged hydrogen bonds between the carbonyl O atom of
Pro365 and the main-chain N atom of Arg368 and His369 may
also help stabilize the unusual orientation of the loop which
could hinder [2Fe–2S] ferredoxin binding (Figs. 5b–5e). When
compared with CYP108A1, there are other significant differ-
ences close to this region. For example, an alanine residue
(Ala374) replaces Trp372 in CYP108A1 and there are several
proline residues in the vicinity of this loop in CYP108D1
which may have an effect on the secondary structure
(Supplementary Fig. S3).
These differences in the topology and electrostatic potential
of the CYP108D1 proximal face versus those of the CYP101
and CYP108A1 enzymes may result in weak interactions
and therefore the low activities observed with the [2Fe–2S]
ferredoxins. There is also a short protruding helix before the
haem-binding proximal loop (Met338–Cys345) in CYP101C1
from the same bacterium, which results in a different surface
topology compared with those of CYP101D1 and CYP101D2,
which are similar to CYP108A1 and CYP101A1 (Supple-
mentary Fig. S14b). A comparison of the CYP101C1 sequence
with those of other CYP101-family members and CYP108A1
and CYP108D1 in this region reveals that a unique two-
amino-acid insertion (Gly329-Leu330) is located before this
short helix (Ma et al., 2011). Additionally, a proline residue
(Pro332) resides within it in a similar location to Pro365 of
CYP108D1.
In order to explore whether the protruding loop is
responsible for the slow electron transfer, Pro365 of
CYP108D1 was replaced by valine. This would remove the
rigid proline residue and potentially realign the loop, or at
least make it less rigid. It was hoped that such a change would
enable a rearrangement of this loop in CYP108D1 to facilitate
ferredoxin binding. However, the activity of the Pro365Val
mutant was not enhanced with any of the ferredoxins tested
(data not shown). It is possible that the loop may not have
realigned in the mutant owing to the extensive hydrogen-
bonding network, which is absent for the short helix in
CYP101C1, or the different location of the prolines. These
differences may make the short helix in CYP101C1 more
flexible than the loop in CYP108D1 and allow fast electron
transfer from Arx. Alternatively, the protrusion may not be
the sole or the dominant cause of the low activity.
3.5. The thermodynamics and kinetics of the first electron
transfer
Ferredoxin recognition and binding determines the
formation constant of the ferredoxin–CYP complex, the
redox-centre separation and the reorganization energy for
intra-complex electron transfer. Non-optimal binding orien-
tations of a nonphysiological ferredoxin might require
conformation changes in the activation step which will
increase the activation energy of electron transfer. The
electron-transfer rate constant is also affected by the ther-
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modynamic driving force for the reaction (Sligar & Gunsalus,
1976).
The reduction potentials of substrate-free CYP108D1 and
the phenylcyclohexane complex were determined by spectro-
electrochemical titrations. The low-spin substrate-free form
showed a reduction potential of 432  8 mV (Fig. 6a), which
is within the range commonly observed for P450 enzymes
(Whitehouse et al., 2011; McLean et al., 2006). The potential
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Figure 5
(a) The electrostatic potential of the proximal face of CYP108D1. Positively and negatively charged regions are shown in blue and red, respectively.
Positively charged residues and those which align with positively charged residues in CYP101C1, CYP101D1 and CYP101D2 are labelled
(Supplementary Fig. S14a). (b) A proximal-face comparison of CYP108D1 (grey) and CYP108A1 (salmon), highlighting the similar positioning of the
proximal loop (shown in blue in CYP108D1 and red in CYP108A1) and the different orientation of the loop region from residues Pro365 to Arg368 of
CYP108D1 (shown in magenta in CYP108D1 and green in CYP108A1). (c) A close-up view of the orientation of the loop region from residues Pro365 to
Arg368, the proximal loop and the haem of CYP108D1 compared with CYP108A1 (coloured as in b). (d) The 2mFo  DFc density of the loop region
from residues Pro365 to Arg368 contoured at0.35 e A˚3. (e) The orientation of the loop region from residues Pro365 to Arg368 in CYP108D1 (wheat)
differs significantly from that in other CYP enzymes and leads to a different topology of the proximal face. Pro365 forces the loop to protrude out from
the proximal face where it interacts with the K and L helices. The hydrogen bonds between these regions and within the loop are shown as dashed lines,
with the bridging water molecules highlighted in red.
for the phenylcyclohexane complex (95% high-spin haem) was
found to be 401  4 mV (Fig. 6b). This highly reducing
potential is unusual since a shift of the P450 haem spin state to
high spin is commonly associated with changes in haem liga-
tion and as a consequence the reduction potential shifts to
more oxidizing values, e.g. the potential of CYP101A1 shifts
from 300 to 170 mV on camphor binding and that of
P450BM3 shifts from 449 to 317 mV on palmitate binding
(Gunsalus et al., 1973; Whitehouse et al., 2010).
The redox potential of Arx was determined to be 248 
14 mV (Fig. 6c) and therefore the reduction of phenylcyclo-
hexane-bound CYP108D1 is endoergic by 170 meV. Even
with oxygen binding to the ferrous deoxy species, the overall
equilibrium constant for the formation of the ferrous-oxy
intermediate from the ferric haem–substrate complex will be
small, since the binding constant for oxygen is typically
103–104 M1 and hence the macroscopic observed turnover
rate will be lower (Honeychurch et al., 1999). For comparison,
the reduction potential of Pdx is 240 mV, increasing to
190 mV in the Pdx–CYP101A1 complex (Martinis et al.,
1996; Sligar & Gunsalus, 1976). The redox potentials of
substrate-free and camphor-bound CYP101D1, which has a
high activity with the ArR–Arx electron-transfer system, were
found to be 419  15 and 205  10 mV, respectively
(Fig. 6d), suggesting that a similar substrate-gating mechanism
for the first electron-transfer step to that observed with
CYP101A1 is in operation (Sligar & Gunsalus, 1976).
The reasons behind the small shift in the redox potential
of CYP108D1 on substrate binding are unclear. The crystal
structure shows only two ordered water molecules in the
active site, with Wat266 being offset from the haem iron,
although other disordered water molecules may be present.
The electronic spectra and redox potential at ambient
temperature show that the haem in the substrate-free form
is almost entirely low spin (Figs. 6 and S6) and the low-
temperature EPR spectra show only a minor contribution
from a high-spin haem (Supplementary Fig. S11). The small
change in redox potential on substrate binding despite the
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Figure 6
Mediated equilibrium spectroelectrochemical titrations of (a) substrate-free CYP108D1, (b) phenylcyclohexane-bound CYP108D1, (c) Arx and (d)
camphor-bound CYP101D1. In each case, the black line is the fully oxidized form of the enzyme and the red line is the fully reduced form, with interim
titrations being shown in other colours and the arrows indicating the sense in which the spectral features change as the haem iron is reduced. The insets
show nonlinear least-squares fits of absorbance at 465 nm to a sigmoidal form of the Nernst equation with the number of electrons fixed at one.
change in the haem spin state from low to high spin may be
linked to the low number of water molecules in the active site
and the offset nature of the FeII-bound water or the out-of-
plane haem iron. It has been postulated that an offset distal
water may lead to a lower reorganization energy, which should
assist in substrate binding (Honeychurch et al., 1999; White-
house et al., 2009). Such an offset water molecule coupled to
an out-of-plane haem iron has been observed in structures
of the substrate-bound form of the wild type and the I401P
mutant of the CYP102A1 enzyme. However, in both of these
forms of CYP102A1 the spin-state equilibrium is shifted
significantly towards high spin and the reduction potential
is more oxidizing (e.g. –302 mV for I401P; Haines et al., 2001;
Whitehouse et al., 2009). If the number of water molecules
in the active site of CYP108D1 is low, substrate binding and
dehydration would induce less of a change in the polarity,
which could lead to a smaller increase in the redox potential.
The volume of the active site was calculated to be 190 A˚3
(using VOIDOO) and excess disordered water in the absence
or the presence of substrate (phenylcyclohexane, 174 A˚3;
phenanthrene, 172 A˚3) may be freer to interact with the polar
haem surface and stabilize the ferric state (Supplementary
Fig. S15; Kleywegt & Jones, 1994). However, this volume may
be reduced if the enzyme has a more closed conformation in
the presence of substrate in solution. Using VOIDOO, the
volume of the active site of CYP108A1 was calculated to be
225 A˚3, which is slightly larger than that for CYP108D1. For
comparison, the active-site volumes of other CYP enzymes are
CYP101A1 (P450cam; PDB entry 1phc; Poulos et al., 1986),
79 A˚3; CYP2E1 (PDB entry 3e6i; Porubsky et al., 2008),
190 A˚3; CYP2A6 (PDB entry 1z10; Yano et al., 2005), 230 A˚3;
CYP1A2 (PDB entry 2hi4; Sansen et al., 2007), 406 A˚3;
CYP3A4 (PDB entry 1tqn; Yano et al., 2004), 1508 A˚3
(McLean et al., 1998, Porubsky et al., 2008). The lower
reduction potential of substrate-free CYP108D1 may also
result from differences in the active-site and haem-ligation
environment, which have been proposed to be important in
determining the spin state and therefore the redox potential
of P450 enzymes (Loew & Harris, 2000). Alternatively, other
substrates may be required to induce a larger shift in the redox
potential and therefore promote electron transfer.
The endoergicity of the electron-transfer step also increases
the activation energy, according to the Marcus equation.
However, the reorganization energy (typically 1–1.5 eV) is the
dominant factor and the rate of the forward electron-transfer
step can be significant even for unfavourable driving forces
(Honeychurch et al., 1999). Therefore, the rate constant for
formation of the FeII(CO) complex (kf) via ferredoxin-to-
haem electron transfer followed by rapid trapping by CO was
determined for the Arx–CYP108D1–phenylcyclohexane and
Arx–CYP101D1–camphor reactions. Since CO binding is
much faster than the electron-transfer step, kf is an acceptable
surrogate for ket, the intra-complex electron-transfer rate
constant.
Stopped-flow experiments showed that the first electron-
transfer rate of Arx–CYP108D1 with phenylcyclohexane is
negligible, which agrees with the slow NADH consumption
(Supplementary Fig. S16). The behaviour of the Arx–
CYP101D1–camphor system is more typical of a class I
electron-transfer system. The data show a fast phase asso-
ciated with the active camphor-bound enzyme (Supplemen-
tary Fig. S16). The kf value for the fast phase was 22.9 0.8 s1
(1 mM P450, 2.5 mM Arx), compared with an NADH-
consumption rate of 30.8  0.6 s1 (0.5 mM P450, 5 mM Arx)
and a kcat of 41 0.6 s1 (Yang et al., 2010). The observed rate
of the first electron-transfer step therefore reflected the
NADH-consumption activities of CYP101D1 and CYP108D1
with the ArR–Arx electron-transfer system.
One possibility is that CYP108D1 utilizes a ferredoxin with
a greater reducing potential. The genome sequence of
N. aromaticivorans reveals that many other potential ferre-
doxin genes are present, e.g. 12 [2Fe–2S] and six [4Fe–4S]
ferredoxins are found. While these are not associated with
CYP108D1, they are possible electron-transfer partners.
Alternatively, CYP108D1 may utilize a different electron-
transfer system which may not contain an Fe–S ferredoxin
(Hannemann et al., 2007; Hawkes et al., 2002).
In summary, CYP108D1 from N. aromaticivorans and
CYP108A1 (P450terp) share a similar fold and both have an
affinity for -terpineol. However, both the access channel and
the active site of CYP108D1 are more hydrophobic. Further-
more, the access channel of CYP108D1, which is important for
substrate recognition and capture, is more spacious compared
with that of CYP108A1. Consequently, CYP108D1 has a
preference for more hydrophobic substrates, including
aromatic hydrocarbons with up to three fused rings. The
docking of phenylcyclohexane and phenanthrene into the
active site predicts the binding mode of these aromatic
compounds and for phenylcyclohexane agrees with the
product profile observed. Hydrophobic interactions, including
those with three Phe residues, appear to be important in
the enzyme–substrate interaction. The redox potential of
CYP108D1 does not shift by as much as expected when
phenylcyclohexane binds, resulting in unfavourable thermo-
dynamics with [2Fe–2S] ferredoxins for the first electron-
transfer step. There are also electrostatic and topological
differences on the CYP108D1 proximal face which may result
in poor complementarity with the tested ferredoxins, resulting
in the low activities observed. An alternative ferredoxin or a
nonferredoxin electron-transfer partner is required to opti-
mize the activity of CYP108D1. CYP108D1 has the potential
to be used as an aromatic hydrocarbon monooxygenase in
biocatalysis or bioremediation and may play a role in the
metabolism and degradation of aromatic compounds by
N. aromaticivorans. Efforts are continuing to further deter-
mine its substrate range and to find an efficient electron-
transfer system.
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